Radioiodine therapy in Graves' disease

Not Applicable

Recruiting

• Conditions: Thyrotoxicosis with diffuse goiter; Graves.

• Registration Number: IRCT2016020217006N1
• Lead Sponsor: Mashhad University of Medical Sciences, Vice chancellor for research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2018-02-22

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

Age more than 18; Confirmed cases of Graves' disease; No previous history of radioiodine therapy;No previous history of thyroid surgery
Exclusion criteria: pregnancy; lactation; severe ophtalmopathy; no desire to join to study

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
TSH, T3, T4. Timepoint: 1,3,6,12 months post radioiodine therapy. Method of measurement: Blood test.;Thyroid volume. Timepoint: 1,3,6,12 months post radioiodine therapy. Method of measurement: Ultrasonography.;Thyroid weight. Timepoint: 1,3,6,12 months post radioiodine therapy. Method of measurement: Physical examination.